低分子肝素钙联合多巴胺和酚妥拉明治疗肺心病并发心力衰竭疗效评价

Low molecular weight heparin calium combined dopamine and phentolamine in treatment of pulmonary heart disease and cardiac failure

目的探讨低分子肝素钙联合多巴胺和酚妥拉明治疗肺源性心脏病(肺心病)并发心力衰竭临床疗效。方法将该院2012年2月至2013年2月收治的118例肺心病并发心力衰竭患者随机分为对照组和观察组,各59例,两组患者均行吸氧、祛痰、平喘、抗炎、利尿等基础治疗,对照组给予低分子肝素钙治疗,观察组在此基础上予以多巴胺和酚妥拉明治疗。观察治疗10 d后两组患者的临床疗效及相关指标。结果治疗后,观察组患者治疗总有效率[91.5%(54/59)]显著高于对照组[74.6%(44/59)],差异有统计学意义(P<0.05);观察组患者临床症状和体征、动脉血气分析、心功能以及血液流变学指标改善情况均优于对照组,差异均有统计学意义(P<0.05)。结论低分子肝素钙联合多巴胺和酚妥拉明治疗肺心病并发心力衰竭,能显著改善患者血流动力学和心肺功能,疗效确切,值得推广应用。

Objective To explore the clinical therapeutic effect of low molecular weight heparin combined with dopamine and phentolamine in treatment of pulmonary heart disease and cardiac failure. Methods A total of 118 patients with pulmonary heart disease and cardiac failure in this hospital from February 2012 to February 2013 were randomly divided into the control group and the treatment group,59 of each group. The two groups were treated with basic therapies,such as oxygen inhalation,phlegm elimination, asthma relief,anti-inflammatory,diuretic treatments. The control group was given low molecular weight heparin while the treatment group with an extra dopamine and phentolamine based on the control group. The clinical efficacy and re-lated indicators of the two groups were observed 10 days after the treatment. Results After the treatment,the total effective rate of the control group was higher than that of the control group[91.5%（54/59） vs 74.6%（44/59）],and there was a significant difference between them（P〈0.05）;The improvement of arterial blood gas analysis and hemorheology indexes of the treatment group were much higher than those of the control group（P〈0.05）. Conclusion The low molecular weight heparin combined with dopamine and phentolamine could significantly improve the patients′ hemodynamics and cardiopulmonary function in treatment of pulmonary heart disease and cardiac failure,which should be worthy to be applied and promoted widely.